Insights & news

Belgium - New Combined Reimbursement Rules for Personalised Medicines and Companion Diagnostics

  • 11/06/2019
  • Articles

The Belgian Official Journal of 5 June 2019 contains two Royal Decrees that create the regulatory framework for the combined reimbursement procedure of personalised medicines and companion diagnostics (“CDx”) in accordance with the tight reimbursement deadlines that apply to medicines but did not previously govern the CDx. As a result, the reimbursement of new CDx (or predictive biomarkers) often lagged that of the associated medicines and resulted in a reimbursement gap.
The new combined reimbursement procedure involves the cooperation of bodies responsible for respectively medicines and CDx in a “Platform CDx” and implies a single Health Technology Assessment of the “package” that consists of the medicine and the predictive biomarker. The Minister of Social Affairs will authorise or reject the package for reimbursement in a single reimbursement decision.
The combined reimbursement procedure will also entail the registration of all reimbursed tests and of the test results. In future, these will allow for more informed policy decisions regarding personalised medicine and the reimbursement of healthcare services in this area.
The modified regulatory framework consists of a new chapter VIII dedicated to personalised medicines in Annex 1 to the Royal Decree of 1 February 2018 governing the reimbursement of medicines. In addition, the list of categories of healthcare services (“nomenclatuur van geneeskundige verstrekkingen”/“nomenclature des prestations de santé”) contained in the annex to the Royal Decree of 14 September 1984 was expanded with a new Article 33ter that will specifically contain a category of CDx and will be updated frequently to reflect technological and scientific developments.
The new rules will enter into force on 1 July 2019.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 04/06/2020
    • Articles

    Europe - Four-Country Inclusive Vaccine Alliance In Quest for Covid-19 Vaccine

    In a letter to Parliament and a press release (see, attachments), the Dutch Minister for Public Health, Wellbeing and Sports, Hugo de Jonge, revealed on 3 June 2020 an initiative of Italy, France, Germany and The Netherlands to work together to secure a Covid-19 vaccine for “the European Union and other countries”.   According to the Minister, the “Inclusive Vaccine Alliance” (IVA) is in talks with several pharmaceutical companies regarding promising ventures and in the process hopes to establish a European manufacturing base for the vaccine. The IVA’s ultimate goal is to create a medicine that is “accessible, available and affordable”.   Other countries will be given the opportunity to join the IVA which is also in contact with the European Commission.

    Read more
    • 03/06/2020
    • Articles

    European Commission Publishes Roadmap Towards Pharmaceutical Strategy for Europe

    The European Commission (the Commission) published on 2 June 2020 its roadmap towards a Pharmaceutical Strategy for Europe (PSE) which it plans to publish in the fourth quarter of 2020 (see, attachment). The roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE. While the Commission will consult a range of stakeholders, it has already announced a public consultation which will run until 7 July 2020.

    Read more
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *